Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?  

作　　者：Ligong Lu Hui Zhang Meixiao Zhan Jun Jiang Hua Yin Danielle JDauphars Shi-You Li Yong Li You-Wen He 

机构地区：[1]Zhuhai Interventional Medical Center,Zhuhai Precision Medical Center,Zhuhai People's Hospital,Zhuhai Hospital Affiliated with Jinan University,Zhuhai 519000,China [2]First Affiliated Hospital,China Medical University,Shenyang 110001,China [3]tricision Biotherapeutic Inc.,Zhuhai 519041,China [4]Department of Immunology,Duke University Medical University Medical Center,Durham,NC 27710,USA

出　　处：《Science China(Life Sciences)》2020年第12期1833-1849,共17页中国科学（生命科学英文版）

基　　金：supported by the National Key Research and Development Program of China(2017YFA0205200);the National Natural Science Foundation of China(81571785,81771957,81901857,81801811);Natural Science Foundation of Guangdong Province,China(2018A030313074)to Dr.Ligong Lu;the Zhuhai Municipal Science and Technology Foundation(ZH22046301200004PWC)to Dr.Shi-You Li;the Sunny Li Family fund to You-Wen He。

摘　　要：The newly emerged severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019(COVID-19) due to SARSCoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARSCoV-2 infection is a critical determinant for patients’ outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.

关 键 词：COVID-19 SEROCONVERSION neutralizing antibody spike protein SARS-CoV-2 convalescent plasma VACCINE 

分 类 号：R563.1[医药卫生—呼吸系统] R392-33[医药卫生—内科学]